You have 9 free searches left this month | for more free features.

City

Guangzhou (1)

Rochester (1)

Condition

Charcot-Marie-Tooth Disease (CMT) (1)

Phosphomannomutase 2 Congenital Disorder of Glycosylation (1)

Phosphomannomutase 2 Deficiency (1)

Phosphomannomutase II Congenital Disorder of Glycosylation (1)

Phosphomannomutase II Deficiency (1)

Pmm2-CDG (1)

Triple Negative Breast Cancer (1)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Terminated (1)

Sign in for free

Phase

phase 2 (2)

phase 3 (1)

Sponsor

Maggie's Pearl, LLC (1)

Sun Yat-sen University (1)

The Third Xiangya Hospital of Central South University (1)

Collaborator

Intervention

epalrestat (3)

placebo (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Other (2)

Industry (1)

Study Type

Interventional (3)

epalrestat

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Charcot-Marie-Tooth Disease (CMT) Trial (Epalrestat)

Not yet recruiting

Charcot-Marie-Tooth Disease (CMT)

Epalrestat

(no location specified)

Mar 22, 2023

Pmm2-CDG, Phosphomannomutase 2 Deficiency, Phosphomannomutase 2 Congenital Disorder of Glycosylation Trial (Epalrestat, Placebo)

Recruiting

Pmm2-CDG
+4 more

Epalrestat
Placebo

Rochester, Minnesota

Mayo Clinic

Oct 25, 2022

Triple Negative Breast Cancer Trial in Guangzhou (Epalrestat)

Terminated

Triple Negative Breast Cancer

Epalrestat

Guangzhou, Guangdong, China

Sun Yat-sen University, Cancer Center

Jan 26, 2021